RedHill Biopharma Ltd (RDHL) - Medical Equipment - Deals and Alliances Profile
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for the treatment of inflammatory and gastrointestinal diseases and cancer. The companys pipeline products include oral combination therapy candidates for the treatment of helicobacter pylori infection, crohns disease and multiple sclerosis; uPA inhibitor for the treatment of gastrointestinal and other solid tumor cancers; Hsp27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers; oral thin film formulation of rizatriptan which is intended for the treatment of acute migraines. Its products under development also intended for the treatment of bowel cleanser, IBS-D, and other indications. RedHill is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd (RDHL) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for the treatment of inflammatory and gastrointestinal diseases and cancer. The companys pipeline products include oral combination therapy candidates for the treatment of helicobacter pylori infection, crohns disease and multiple sclerosis; uPA inhibitor for the treatment of gastrointestinal and other solid tumor cancers; Hsp27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers; oral thin film formulation of rizatriptan which is intended for the treatment of acute migraines. Its products under development also intended for the treatment of bowel cleanser, IBS-D, and other indications. RedHill is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd (RDHL) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
2
List of Tables 3
List of Figures 4
RedHill Biopharma Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
RedHill Biopharma Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 6
RedHill Biopharma Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
RedHill Biopharma Ltd, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
RedHill Biopharma Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
RedHill Biopharma Ltd, Medical Equipment, Deal Details 10
Partnerships 10
RedHill Biopharma Enters Into Licensing Agreement With UCF Research Foundation 10
RedHill Biopharma Enters Into Co-Development Agreement With Quest Diagnostics To Develop MAP Test For Crohns Disease 10
Equity Offering 11
RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD1.4 Million 11
RedHill Biopharma Withdraws Public Offering of ADSs 13
RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 14
RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 15
RedHill Biopharma Completes Private Placement Of Shares And Warrants For US$11.7 Million 16
RedHill Biopharma Completes Private Placement Of Units For US$8.5 Million 18
RedHill Biopharma Ltd - Key Competitors 20
Key Employees 21
Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Feb 23, 2017: RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results 23
Nov 14, 2016: RedHill Biopharma Reports 2016 Third Quarter Financial Results 25
Jul 26, 2016: RedHill Biopharma Reports 2016 Second Quarter Financial Results 28
Apr 20, 2016: RedHill Biopharma Reports 2016 First Quarter Financial Results 31
Feb 25, 2016: RedHill Biopharma Reports 2015 Fourth Quarter and Full-Year Financial Results 33
Corporate Communications 37
Feb 17, 2016: RedHill Biopharma Appoints Dr. June S. Almenoff and Ms. Theresa M. Stevens to Advisory Board 37
Other Significant Developments 38
Aug 11, 2016: RedHill Biopharma Provides 2016 Semi-Annual R&D Update 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List Of Tables
RedHill Biopharma Ltd, Medical Equipment, Key Facts, 2015 1
RedHill Biopharma Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
RedHill Biopharma Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
RedHill Biopharma Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 6
RedHill Biopharma Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
RedHill Biopharma Ltd, Deals By Market, 2011 to YTD 2017 8
RedHill Biopharma Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
RedHill Biopharma Enters Into Licensing Agreement With UCF Research Foundation 10
RedHill Biopharma Enters Into Co-Development Agreement With Quest Diagnostics To Develop MAP Test For Crohns Disease 10
RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD1.4 Million 11
RedHill Biopharma Withdraws Public Offering of ADSs 13
RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 14
RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 15
RedHill Biopharma Completes Private Placement Of Shares And Warrants For US$11.7 Million 16
RedHill Biopharma Completes Private Placement Of Units For US$8.5 Million 18
RedHill Biopharma Ltd, Key Competitors 20
RedHill Biopharma Ltd, Key Employees 21
List Of Figures
RedHill Biopharma Ltd, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
RedHill Biopharma Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
RedHill Biopharma Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
RedHill Biopharma Ltd, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
RedHill Biopharma Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
RedHill Biopharma Ltd, Medical Equipment, Deals by Type, 2011 to YTD 2017 6
RedHill Biopharma Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
RedHill Biopharma Ltd, Medical Equipment, Deals by Market, 2011 to YTD 2017 8
RELATED REPORTS
RedHill Biopharma Ltd - Strategic SWOT Analysis Review
RedHill Biopharma Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information
View ReportiX Biopharma Ltd (42C) - Financial and Strategic SWOT Analysis Review
iX Biopharma Ltd (42C) - Financial and Strategic SWOT Analysis Review
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
